Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 639667 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design)

Trial Profile

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 639667 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design)

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2014

At a glance

  • Drugs BI 639667 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 14 Jul 2014 Planned End Date changed from 1 Sep 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov record.
    • 14 Jul 2014 Planned primary completion date changed from 1 Sep 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov record.
    • 13 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top